AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone. It has been studied mainly in relation to lipid metabolism and body-weight research. The central evidence point is important: early laboratory and animal studies generated hypotheses, but obesity-focused Phase 2 studies did not show statistically significant weight loss in obese participants. AOD-9604 is therefore best understood as an investigational research subject, not as an established treatment.
What is AOD-9604
AOD-9604, also referred to in later clinical documentation as LAT8881, is a 16-amino-acid peptide. It contains the 15 amino acids corresponding to residues 177 through 191 at the C-terminus of human growth hormone, plus an additional N-terminal tyrosine. The sequence includes a disulfide bridge, a structural feature that helps define the peptide's chemical identity. Public clinical-trial documentation describes this relationship directly and records the earlier obesity-development name AOD-9604.
This origin does not mean that AOD-9604 should be treated as interchangeable with human growth hormone. A peptide fragment can have different pharmacology, stability, exposure, and biological effects from the full hormone. In research reporting, the precise name, sequence context, test system, and study design all matter.
Key facts
• AOD-9604 is a synthetic 16-amino-acid peptide related to the C-terminal region of human growth hormone.
• Early mechanistic work was conducted in cells and animal models; such findings do not establish effects in humans.
• Clinical-trial protocols state that obesity-focused Phase 2 studies did not demonstrate statistically significant weight loss and that development for that indication was discontinued.
• The U.S. Food and Drug Administration notes limited safety information and peptide-quality concerns in its discussion of compounded products containing AOD-9604.
Early research on lipid metabolism
The early research rationale for AOD-9604 came from experiments investigating the C-terminal region of growth hormone and lipid metabolism. A 2001 paper in Endocrinology reported findings in obese mice after chronic treatment. The authors observed changes in body weight, body fat, lipolytic sensitivity, and beta-3 adrenergic receptor RNA expression in that model. They also found that the relationship to beta-3 adrenergic signaling was more complex than a simple direct receptor mechanism.
These results are useful for understanding how a research hypothesis developed, but they are not proof of a clinical outcome. Animal models simplify biological systems, use defined experimental conditions, and cannot answer all questions about human effectiveness or safety. A careful article should not convert a mouse result into a human claim.
What human studies tell us
Later public protocols for LAT8881 summarize the earlier AOD-9604 clinical program. One protocol states that six clinical trials involving 936 subjects were completed, with more than 700 participants treated with oral LAT8881. It reports no significant safety issues in that program but says the most recent obesity-efficacy study, METAOD006, did not meet its primary endpoint; development for obesity was discontinued in 2007.
A subsequent ClinicalTrials.gov protocol states the result in even plainer language: Phase 2 clinical studies did not show statistically significant weight loss in obese subjects. This is the evidence that should anchor any responsible overview of AOD-9604's obesity research history. A larger collection of early preclinical observations does not override the outcome of the human efficacy program.
The same later protocols concern a different investigational context, neuropathic pain, rather than obesity. Their description of LAT8881 should not be read as proof of benefit for any condition. It is evidence that the molecule continued to be investigated, while the question being studied, the route of study, and the endpoints changed.
Why quality and identity are important in peptide research
Peptide research depends on accurately knowing what material is being studied. A peptide name alone is not enough to establish identity, purity, content, or suitability for a particular experiment. Researchers commonly review lot-specific analytical documentation and methods that can characterize identity and impurities. The relevant quality question is not whether a label contains a familiar name; it is whether the material can be traced and analytically characterized for the intended research context.
The FDA specifically notes potential immunogenicity concerns for some routes of administration and complexities related to peptide impurities and active-ingredient characterization for compounded products containing AOD-9604. That statement is not a substitute for a study-specific risk assessment, but it explains why analytical documentation, source traceability, and careful interpretation are central to peptide research communication.
Regulatory and evidence context
Regulatory status and research status are separate questions from molecular identity. The FDA's discussion of AOD-9604 in its compounding-safety materials states that the agency has identified no, or only limited, safety-related information and lacks sufficient information to know whether the substance would cause harm when administered to humans. It also notes reports of serious adverse events that may be associated with AOD-9604, while stating that causality is unclear.
For readers evaluating online claims, this distinction is practical. A product description, an animal study, a protocol summary, and a regulatory notice do not carry the same evidentiary weight. The most direct evidence for an asserted human outcome is a well-designed human study that reports the relevant endpoint. For AOD-9604 and obesity, the publicly available protocol summaries describe an unsuccessful Phase 2 efficacy outcome.
How to read AOD-9604 research responsibly
A responsible reading order starts with the study type. First, identify whether a claim comes from chemistry, a cell system, an animal model, a human trial, or a regulatory document. Second, check what question the study was designed to answer and whether its primary endpoint was met. Third, separate a finding about a related compound name or a later research program from a demonstrated outcome in the original indication. Finally, avoid treating scientific interest as clinical validation.
This approach does not dismiss early-stage research. It places it in the correct category. AOD-9604 remains a useful example of why peptide research needs precise terminology, transparent sourcing, and a clear line between preclinical rationale and human evidence.
Frequently asked questions
Is AOD-9604 the same as human growth hormone?
No. AOD-9604 is a synthetic peptide fragment related to the C-terminal region of human growth hormone, with an added tyrosine. It is not the full hormone.
Did human obesity studies show significant weight loss?
Public ClinicalTrials.gov protocols describing the earlier program state that Phase 2 obesity studies did not show statistically significant weight loss and that development for the obesity indication was discontinued.
Why do animal findings need careful interpretation?
Animal and laboratory models can help generate biological hypotheses, but they do not by themselves establish human effectiveness or safety.
Key takeaway
AOD-9604 is a defined synthetic peptide that has generated preclinical interest in lipid-metabolism research. The decisive human-evidence context for its original obesity-development program is that Phase 2 studies did not demonstrate statistically significant weight loss. Any discussion should keep that result, the limits of preclinical evidence, and the need for quality documentation in view.
Related resources
• Related metabolic research articles
Sources
• Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism following chronic treatment in obese mice and beta3 AR knock out mice. Endocrinology. 2001;142(12):5182-5189. https://pubmed.ncbi.nlm.nih.gov/11713213/
• Lateral Pharma. Protocol LAT-NP-001. A Phase IIa study of the efficacy and safety of oral LAT8881 in patients with neuropathic pain. ClinicalTrials.gov document. https://cdn.clinicaltrials.gov/large-docs/53/NCT03865953/Prot_000.pdf
• Lateral Pharma. Protocol LAT-NP-002. Official protocol. ClinicalTrials.gov document. https://cdn.clinicaltrials.gov/large-docs/06/NCT05298306/Prot_000.pdf
• U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Disclaimer
For research use only. This educational content is not medical advice and does not describe diagnosis, treatment, dosing, or human or veterinary use.